Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

被引:28
|
作者
Takamatsu, Hiroyuki [1 ]
机构
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Hematol Resp Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
关键词
multiple myeloma; minimal residual disease; allele-specific oligonucleotide-PCR; droplet digital PCR; next-generation sequencing; IG/TCR GENE REARRANGEMENTS; LENALIDOMIDE MAINTENANCE; PLUS DEXAMETHASONE; PERIPHERAL-BLOOD; BONE-MARROW; PHASE-II; BORTEZOMIB; CONSOLIDATION; INDUCTION; THALIDOMIDE;
D O I
10.3390/jcm6100091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is a hematological malignancy with a poor prognosis, characterized by clonal proliferation of plasma cells in the bone marrow (BM). Relapse due to undetected minimal residual disease (MRD) is the leading cause of death among patients with MM. This review summarizes the methods and prognostic value of MRD assessment in BM and autografts from MM patients who underwent autologous stem cell transplantation (ASCT) by multiparameter flow cytometry (MFC), allele-specific oligonucleotide real-time quantitative PCR (ASO-qPCR), droplet digital PCR (ddPCR), and next-generation sequencing (NGS)-based detection methods. MRD assessment using NGS-based approaches has clear prognostic value and better sensitivity compared to traditional methods.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms' tumor 1 expression
    Rossi, Giovanni
    Carella, Angelo Michele
    Minervini, Maria Marta
    di Nardo, Francesco
    de Waure, Chiara
    Greco, Michele Mario
    Merla, Emanuela
    de Cillis, Giovanni Pio
    Di Renzo, Nicola
    Melpignano, Angela
    Capalbo, Silvana
    Palumbo, Gaetano
    Pisapia, Giovanni
    Cascavilla, Nicola
    LEUKEMIA RESEARCH, 2015, 39 (02) : 138 - 143
  • [42] The Value of Minimal Residual Disease as a Progression-Free Survival Predictor After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients
    Solovev, Maxim
    Mendeleeva, Larisa
    Firsova, Maiia
    Julhakyan, Hunan
    Galtseva, Irina
    Davydova, Julia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S324 - S324
  • [43] Autologous stem cell transplantation (ASCT) is still crucial for multiple myeloma (MM) patients with undetectable minimal residual disease after induction treatment
    Yan, Wenqiang
    Liu, Jiahui
    Fan, Huishou
    Xu, Jingyu
    Cui, Jian
    Qiu, Lugui
    Zou, Dehui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S117 - S118
  • [44] ERADICATION OF MINIMAL RESIDUAL DISEASE, ANALYZED BY PCR, AFTER DOUBLE HIGH-DOSE CHEMORADIOTHERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA
    BJORKSTRAND, B
    LJUNGMAN, P
    BIRD, JM
    SAMSON, D
    GAHRTON, G
    BLOOD, 1994, 84 (10) : A208 - A208
  • [45] PREDICTIVE ROLE OF MINIMAL RESIDUAL DISEASE BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A COMPARISON BETWEEN MULTIPARAMETER FLOW CYTOMETRY AND WILM'S TUMOR 1 EXPRESSION
    Rossi, G.
    Carella, A. Michele
    Minervini, M. Marta
    Savino, L.
    di Nardo, F.
    de Waure, C.
    Greco, M. Mario
    Merla, E.
    Melpignano, A.
    Spirito, A.
    Capalbo, S.
    Palumbo, G.
    Perla, G.
    De Cillis, G. Pio
    Cascavilla, N.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S183 - S183
  • [46] Real time PCR for molecular monitoring of minimal residual disease in multiple myeloma patients undergoing autologous transplantation with in vitro purged hematopoietic stem cells.
    Barbui, AM
    Dotti, G
    Barbui, T
    Rambaldi, A
    BLOOD, 2000, 96 (11) : 184A - 184A
  • [47] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation
    Böttcher, S
    Ritgen, M
    Pott, C
    Brüggemann, M
    Raff, T
    Stilgenbauer, S
    Döhner, H
    Dreger, P
    Kneba, M
    LEUKEMIA, 2004, 18 (10) : 1637 - 1645
  • [48] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation
    S Böttcher
    M Ritgen
    C Pott
    M Brüggemann
    T Raff
    S Stilgenbauer
    H Döhner
    P Dreger
    M Kneba
    Leukemia, 2004, 18 : 1637 - 1645
  • [49] Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
    Martinelli, G
    Terragna, C
    Zamagni, E
    Ronconi, S
    Tosi, P
    Lemoli, RM
    Bandini, G
    Testoni, N
    Amabile, M
    Ottaviani, E
    Buonamici, S
    Soverini, S
    Montefusco, V
    De Vivo, A
    Bonifazi, F
    Tura, S
    Cavo, M
    HAEMATOLOGICA, 2000, 85 (09) : 930 - 934
  • [50] The detection of residual disease by flow cytometry or IGH PCR within 12 months of autologous stem cell transplantation for CLL is associated with an increased risk of relapse.
    Dasgupta, RK
    Matutes, E
    Davies, FE
    Fernandes, S
    Evans, P
    Catovsky, D
    Milligan, D
    Morgan, GJ
    BLOOD, 2002, 100 (11) : 862A - 862A